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Abstract
Background: In Guinea-Bissau HIV-1, HIV-2, and HTLV-I are prevalent in the general population.
The natural history of HIV/HTLV-I single and dual infections has not been fully elucidated in this
population. Previous studies have shown that combinations of these infections are more common
in older women than in men. The present study compares mortality associated with HIV-1, HIV-2,
and HTLV-I single and dual infections in individuals over 35 years of age within an urban community-
based cohort in Guinea-Bissau.
Results: A total of 2,839 and 1,075 individuals were included in the HIV and HTLV-I mortality
analyses respectively. Compared with HIV-negative individuals, adjusted mortality rate ratios
(MRRs) were 4.9 (95% confidence interval (CI): 2.3, 10.4) for HIV-1, 1.8 (95%CI: 1.5, 2.3) for HIV-
2, and 5.9 (2.4, 14.3) for HIV-1/HIV-2 dual infections. MRR for HTLV-I-positive compared with
HTLV-I-negative individuals was 1.7 (1.1, 2.7). Excluding all HIV-positive individuals from the
analysis, the HTLV-I MRR was 2.3 (1.3, 3.8). The MRR of HTLV-I/HIV-2 dually infected individuals
was 1.7 (0.7, 4.3), compared with HIV/HTLV-I-negative individuals. No statistically significant
differences were found in retrovirus-associated mortality between men and women.
Conclusion: HIV-1-associated excess mortality was low compared with community studies from
other parts of Africa, presumably because this population was older and the introduction of HIV-
1 into the community recent. HIV-2 and HTLV-I-associated mortality was 2-fold higher than the
mortality in uninfected individuals. We found no significant differences between the mortality risk
for HIV-2 and HTLV-I single infection, respectively, and HIV-2/HTLV-I dual infection. The higher
prevalence of retroviral dual infections in older women is not explained by differential retrovirus-
associated mortality for men and women.
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Background
Guinea-Bissau constitutes a unique area in which the
three major retroviruses HIV-1, HIV-2 and HTLV-I circu-
late in the general population [1-8]. The natural history of
these infections and co-infections is not fully understood
in this area. Previously, we have found that various com-
binations of dual infections of these viruses were more
common in women than in men, a trend particularly
strong for individuals over 45 years of age[4,5,7,8]. Also in
a rural population aged 15 years and over in the same
country, we found a strong association between HIV-2
and HTLV-I in women but not in men [7]. Various factors
could contribute to these age and gender patterns of retro-
viral infections. When behavioural factors were included
in the analyses our observations were not modified [8].
Differential mortality of retrovirus infections between
men and women, compared with retrovirus-negative indi-
viduals, could contribute; if retrovirus-infected men have
higher mortality than retrovirus-infected women, com-
pared with negative individuals, a higher prevalence of
retrovirus infections would be observed among older
women. Few studies have investigated mortality associ-
ated with HIV-1/HIV-2 dual infection [9,10], and it is
unclear whether there are any differences between men
and women. Regarding HIV-1 mortality, there is usually
no difference between men and women [11-14], although
a higher mortality rate for HIV-1-positive men was
observed in a professional cohort in Tanzania [15]. HIV-1
mortality studies from community settings in West Africa
are scarce [10]. For HIV-2 infections no difference in mor-
tality between men and women was observed either [16-
18]. However, none of these studies have examined
whether the male-to-female (M/F) mortality ratio differs
for HIV-infected and uninfected individuals. In addition,
there are few studies addressing HTLV-I-associated mor-
tality in a general population in Africa [4,19].
Hence, we investigated the mortality patterns of HIV-1,
HIV-2, and HTLV-I, single and dual infections as well as
non-retrovirus infections in the capital Bissau. The objec-
tive was also to assess whether the age- and gender-specific
patterns of dual retroviral infections could be related to
mortality patterns.
Results
Participation
A total of 2,839 of the 2,944 individuals were eligible for
inclusion in the HIV mortality analyses, and 1,075 of the
1,124 in the HTLV-I analyses. In the HIV analyses, four
were not re-identifiable, 15 were excluded due to confu-
sion as to identity or uncertainty about age, and 86 indi-
viduals left the study before reaching age 35 (Table 1). The
figures for the HTLV-I mortality sample were 1, 11, and 37
individuals (Table 2). A total of 495 (162) individuals
moved and 517 (170) died during the follow-up period,
numbers in parenthesis indicating individuals in the
HTLV-I mortality sample. Tables 1 and 2 display the out-
come with regard to HIV/HTLV status and gender. Total
follow-up time was 12,283 and 4,022 years for subjects
included in the HIV and HTLV-I analyses, with a median
follow-up time of 3.8 years (range 0.0–12.4) and 3.0 years
(0.0–10.5) respectively. Median age of participants were
53.2 (interquartile range (IQR) = 45.9–61.0), and 49.4
(IQR = 39.2–58.2), respectively.
General HIV-associated mortality
Sixteen HIV-negative individuals seroconverted during
the follow-up period; 13 to HIV-2, 2 to HIV-1, and 1 dual
HIV-1/HIV-2 infection. Five HIV-2-positive individuals
seroconverted to dual HIV-1/HIV-2 infection. As stated in
the statistical methods these seroconversions were
accounted for in the analyses.
Among the 517 deaths, 277 occurred among men (MR/
1000 pyo = 47.9, 95 percent CI: 42.6, 53.9) and 240
among women (MR = 36.9, CI: 32.5, 41.9). Seven of these
deaths occurred among HIV-1-infected (MR = 116, CI:
52.2, 243), 105 deaths among HIV-2-infected (MR = 62.0,
CI: 51.4, 75.3) and five among HIV-1 + 2 dually infected
(MR = 93.6, CI: 39.0, 225). Overall MRRs, adjusted for
current age, current HIV status and sex were 4.9 (2.3, 10.4)
for HIV-1, 1.8 (1.5, 2.3) for HIV-2, and 5.9 (2.4, 14.3) for
HIV-1/HIV-2 dual infections (Table 3).
In a sub-analysis, possible confounding variables were
tested such as ethnic group, district, schooling, and work-
ing outside home at the time of entry into the study,
because this information was not available for all individ-
uals. Only working outside home was independently
associated with less risk of dying, the MRR corrected for
age and gender being 0.7 (95 percent CI: 0.5, 1.0). The
information about work was available for 1707 individu-
als. Corrected for age, gender, current HIV-status, and
work, the HIV-1-associated MRR was 4.1 (95 percent CI:
1.9, 8.7), for HIV-2 the MRR was 1.7 (95 percent CI: 1.3,
2.4), and for dual HIV it was 11.7 (95 percent CI: 4.7,
29.2).
A total of 809 individuals had an HTLV-I status at the time
of entry into the study. Adjusting for HTLV-I status did not
change the estimates.
Gender-specific HIV-associated mortality
The mortality rate was higher in HIV-negative men than in
women (Table 4), the age-corrected male-to-female (M/F)
MRR being 1.4 (95 percent CI: 1.1, 1.7) in HIV-negative
individuals.Retrovirology 2007, 4:85 http://www.retrovirology.com/content/4/1/85
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HIV-1 mortality
Comparing HIV-1-positive with HIV-negative individuals,
we found the age-corrected MRR to be 5.2 (95 percent CI:
1.9, 14.0) in men and 4.7 (95 percent CI: 1.5, 14.6) in
women (test of homogeneity, p = 0.89) (Table 4). When
we considered both HIV-1 single infection and dual infec-
tions as HIV-1 infection, individuals <45 years of age
tended to have stronger excess mortality compared with
HIV-negative individuals than individuals > = 45, though
the differences were not statistically significant (test of
homogeneity, p = 0.41 in men and p = 0.32 in women)
(Table 5).
HIV-2 mortality
For HIV-2 the age-adjusted MRR was 1.6 (95 percent CI:
1.1, 2.2) in men and 2.1 (95 percent CI: 1.6, 2.8) in
women, test of homogeneity, p = 0.24 (Table 4). Women
<45 had higher HIV-2 associated excess mortality than
women > = 45 (test of homogeneity, p < 0.005). Though
the pattern was the same for men the difference was not
statistically significant (test of homogeneity, p = 0.18)
(Table 5).
HIV-1 + HIV-2 dual mortality
For HIV-1 + 2 dual infection, the age adjusted MRR was
4.3 (95 percent CI: 1.1, 17.3) in men and 7.9 (95 percent
CI: 2.5, 24.9) in women, (test of homogeneity, p = 0.51)
(Table 4).
HTLV-I mortality
One individual seroconverted during follow-up. Twenty-
two HTLV-I-positive (MR = 69.7, CI: 45.9, 106) and 148
HTLV-I-negative individuals (MR = 39.9, cent CI: 34.0,
46.9) died. Overall age- and sex-adjusted HTLV-I MRR,
comparing HTLV-I-positive with HTLV-I-negative individ-
uals, was 1.7 (1.1, 2.7). The age-adjusted MRRs were 1.9
(CI: 0.9, 4.0) and 1.6 (CI: 0.9, 2.8) for men and women
respectively (test of homogeneity, p = 0.78) (Table 6).
Adjusting for possible confounding variables such as
schooling, working outside home, ethnic group, or district
did not change the estimates. When all HIV-positive indi-
viduals were excluded from the analysis, the MRR for
HTLV-I-positive compared with HTLV-I negative individ-
uals was 2.3 (1.3, 3.8) (Table 3).
Table 1: Outcome and mortality rates with regard to HIV status, irrespective of HTLV-I status.
Negative HIV-1 HIV-2 HIV-1 + HIV-2 dual Total
Men Women Men Women Men Women Men Women All
Previous HIV result from 
1987, 1989, 1990, 1992, 
1994 or 1996.
1,250 1,260 10 12 156 243 5 8 2,944
Total re-identified 1,247 1,259 10 12 156 243 5 8 2,940
Confusion/age uncertain 1/0 4/0 0/0 0/0 4/1 4/1 0/0 0/0 13/2
Exit study at age <35. 37 43 0 0 2 4 0 0 86
Total participating in 
analysis:
1,209 1,212 10 12 149 234 5 8 2,839
Seroconvert during 
follow-up time
79 23
(status after sero-
conversion)
(2 HIV-1, 
4 HIV-2 1 
HIV-1/2)
(HIV-2) (HIV-1/2) (HIV-1/2)
Moved (%*) 198 (16.5) 212 (17.6) 4 (33.3) 1 (8.3) 23 (15.2) 51(21.3) 4 (50) 2 (18.2) 495 (17.4)
Died (%*) 229 (19.1) 171 (14.2) 4 (33.3) 3 (25) 42 (27.8) 63 (26.3) 2 (25) 3 (27.3) 517 (18.2)
Median follow-up time in 
years 
3.8 3.9 2.5 3.1 3.8 3.7 3.2 2.6 3.8
(range) (0.0–12.1) (0.0–12.4) (0.2–4.3) (0.4–3.8) (0.1–11.6) (0.1–12.0) (0.3–5.9) (0.6,4.5) (0.0–12.4)
Total follow-up time, 
years
5084 5398 26.9 33.6 648 1039 23.7 29.7 12283
Mortality rate/1000 pyo  45.0 31.7 149 89.3 64.8  60.6  84.3  101 42.1
(95% CI†) (39.5,51.3) (27.3, 36.8) (55.9, 397) (28.8, 278) (47.9, 87.7) (47.3,77.6) (21.1, 337) (32.6, 313) (38.6, 45.9)
Individuals in general urban population cohorts in Guinea-Bissau with an HIV result from any previous survey during 1987–1996 were included in 
the study. The table shows the outcome of the eligible individuals according to HIV status. Some individuals changed HIV status during follow-up, 
from HIV-negative to HIV-1 and/or HIV-2-positive, or from HIV-2 to HIV-1/HIV-2 dually positive. This is shown in the middle section of the table.  
*% of total number participating according to current HIV status. †CI = confidence intervalRetrovirology 2007, 4:85 http://www.retrovirology.com/content/4/1/85
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All retrovirus-associated mortality
We compared mortality for co-infected individuals with
mortality for single infected individuals. Among 1,069
individuals with concurrent HIV and HTLV-I results, the
MRR for individuals infected only with HIV-1 was 8.9 (95
percent CI: 2.1, 38.6), for HIV-2 single infected it was 2.9
(95 percent CI: 2.0, 4.2), and for HTLV-I single infected
2.3 (95 percent CI: 1.3, 3.8). For HIV-1/HIV-2 dual infec-
tions the MRR was 7.0 (95 percent CI: 1.7, 28.7), for HIV-
2/HTLV-I dual infections it was 1.7 (95 percent CI: 0.7,
4.3), and for HIV-1/HIV-2/HTLV-I triple infections it was
6.7 (95 percent CI: 0.9, 50.1). All estimates were com-
pared with HIV and HTLV-I-negative individuals. There
was no significant difference between MRRs for HIV-2 sin-
gle infection, HTLV-I single infection and HIV-2/HTLV-1
dual infection.
Discussion
To our knowledge this is the first study to report compar-
ative mortality rates of HIV-1, HIV-2, and HTLV-I single
and dual infections within the same population in a com-
munity setting in Africa. The population was antiretroviral
treatment naïve at the time of the study; thus these data
reflect the natural development of these infections. Gener-
ally, the HIV-associated mortality was higher compared
with the mortality in non-infected individuals, regardless
of the type of HIV infection and of HTLV-I status. The HIV-
1-associated mortality was 4 to 5-fold increased compared
with the mortality in HIV-negative individuals. This figure
is lower than figures reported from community studies in
other parts of Africa, where 10–20 times higher risks are
frequently found [12,13,20-22], and could be explained
by the differences in the age distribution between our
sample and studies from other areas including mainly
younger adults [12,13,20,21]. Reports on HIV-1-associ-
ated mortality from general populations in West Africa are
scarce [10]. The fact that HIV-1 was introduced recently
into Guinea-Bissau and that the HIV-1 epidemic presum-
ably is still in its early phase could also contribute to the
lower relative mortality compared with the more high
prevalent areas. Another possible explanation could be
variations in disease progression between HIV-1 subtypes
as reported from Senegal [23]. In West Africa, subtype A
seems to be most prevalent [24-26], and studies have indi-
cated that an A/G recombinant form is the most common
in West Africa [26-28], in particular in Guinea-Bissau [28].
For HIV-2 we found 1.5 to 2-fold increased mortality
rates. This is comparable with previous observations from
the same urban [17] and rural general populations [16].
The MRR for dual HIV-1/HIV-2 infection in our study was
more equivalent to the risk we found for HIV-1 and could
Table 3: All retrovirus mortality rates and mortality rate ratios
MR* (95% CI†)M R R ‡(95% CI)
HIV-1 116 (52.2, 243) 4.9§ (2.3, 10.4)
HIV-2 62.0 (51.4, 75.3) 1.8§ (1.5, 2.3)
HIV-1/2 dual 93.6 (39.0, 225) 5.9§ (2.4, 14.3)
HTLV-I all 69.7 (45.9, 106) 1.7# (1.1, 2.7)
HTLV I positive/HIV- negative 77.4 (47.4, 126) 2.3&(1.3, 3.8)
* MR = mortality rate per 1000 person years of observation.
† CI = confidence interval.
‡ MRR = Mortality rate ratio.
§Comparing with HIV-negative.
# Comparing with HTLV-I-negative.
& Comparing with HIV and HTLV-I-negative
Table 2: Outcome and mortality rates with regard to HTLV status, irrespective of HIV-status. Individuals from the same cohorts as in 
table 1 are included, but with an HTLV-1 result from any previous survey
Negative HTLV-I Total
Men Women Men Women All
Previous HTLV result from 1990 or 1996. 497 550 20 57 1,124
Total re-identified with a previous HTLV result 496 550 20 57 1,123
Confusion/age uncertain 4/0 5/0 0/0 2/0 11
Exit study at age <35. 21 16 0 0 37
Total participating in analysis: 471 529 20 55 1,075
Moved (%*) 75 (15.9) 80(15.1) 3 (15%) 4 (7.3) 162 (15.1)
Died (%*) 79 (16.8) 69 (13.0) 7 (35%) 15 (27.2) 170 (15.8)
Median follow-up time in years (range) 2.9 (0.0–9.1) 2.9 (0.0–10.5) 3.0 (0.8–7.8) 3.4 (0.8–9.4) 3.0 (0.0–10.5)
Total follow-up time in years 1703 2004 73.4 242 4022
Mortality rate/1000 pyo (95%CI†) 46.4 (37.2, 57.8) 34.4 (27.2 43.6) 95.4 (45.5, 200) 61.9 (37.8, 103) 42.3 (36.4, 49.1)
*% of total number participating.
† CI = confidence intervalRetrovirology 2007, 4:85 http://www.retrovirology.com/content/4/1/85
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reflect that the clinical outcome of HIV-1 and HIV-2 dual
infection may resemble HIV-1 more than HIV-2 [29-32].
However, there were few dually infected in the study, and
larger studies are needed to determine whether these
trends are reproducible. Few other community studies
have addressed mortality related to HIV-1 and HIV-2 dual
infection [10].
HTLV-I-associated mortality was about 2-fold increased
compared with HTLV-I-negative mortality. The effect was
particularly strong when excluding the HIV-positives from
the analysis. A previous follow-up of individuals aged ≥
50 years in this population did not identify any significant
effect of HTLV-I on survival [4]. A larger number of partic-
ipants and a lower mean age in the present study may
explain this difference. In the rural area of Guinea-Bissau,
a 7-year follow-up of 285 HIV-2-positive and HIV-2-nega-
tive individuals found no increased mortality for HTLV-I.
However, mortality was associated with increased HTLV-I
proviral load [19]. Theoretically contracting HIV during
Table 5: Mortality rates and mortality rate ratios for HIV, irrespective of HTLV-I status. MRs and MRRs below and above 45 years of 
age are compared
HIV-1 and HIV-1 + HIV-2 dually 
infected*
HIV-2 single infected†
Age group Mortality rate/1000 
pyo
MRR‡ 95% CI§ Mortality rate/
1000 pyo
MRR‡ 95% CI§
MEN
<45 45.1(6.4–320) 12.0# 1.4,99.7 17.9(4.5,71.6) 4.8# 1.0,23.6
> = 45 176(73.2–422) 4.6 1.9,11.1 74.6(54.7,102) 1.5 1.1, 2.2
Test of homogeneity of effect modification of age p = 0.41 p = 0.18
WOMEN
<45 46.4(6.5–329) 17.1# 2.1,142 33.4(15.0,74.3) 12.3# 4.0,38.9
> = 45 120(49.8–288) 5.4 2.2,13.1 66.3(51.1,85.9) 1.9 1.4,2.6
Test of homogeneity of effect modification of age p = 0.32 p < 0.005
*Including both HIV-1 single and HIV-1 + HIV-2 dual infections.
†Including only HIV-2 single infections.
‡ MRR = Mortality rate ratio, comparing with HIV-negative.
§ CI = confidence interval.
#The MRRs are different from those in Table 4 as the HIV-1 single and HIV-1 + HIV-2 dually infected have been grouped together in this Poisson 
model (see statistical methods)
Table 4: Mortality rates (MRs) and mortality rate ratios (MRRs) for HIV, according to age and sex, irrespective of HTLV-I status
HIV-negative HIV-1 HIV-2 HIV-1 + HIV-2
Age 
group*
MR†(deaths/
pyo)
MR†(deaths/
pyo)
MRR‡ 95% CI§ MR†(deaths/
pyo)
MRR‡ 95%CI§ MR†(deaths/
pyo)
MRR‡ 95%CI§
MEN
35–44 4.7(4/844) 100(1/10) 21.1 2.4,189 17.9(2/112) 3.8 0.7,20.6 0(0/12.1)
45–54 20.9(28/1342) 235(2/8.5) 10.3 2.7,47.3 46.9(9/192) 2.2 1.1,4.8 320(2/6.3) 15.3 3.6,64.3
55–64 45.5 (81/1781) 0 (0/4.6) 81.7(18/220) 1.8 1.1,3.0 0 (0/5.3)
65–74 88.2 (65/737) 268(1/3.7) 3.0 0.4,21.9 124 (13/104) 1.4 0.8,2.6 0 (0/0)
75+ 134 (51/380) 0 (0/0) 0(0/19.9) 0 (0/0)
Total: 45.0(229/5084) 148.8(4/26.9) 5.2# 1.9,14.0 64.8(42/648) 1.6# 1.1, 2.2 84.3 (2/23.7) 4.3# 1.1,17.3
WOMEN
35–44 1.9 (2/1040) 0(0/11.3) 33.3(6/180) 17.4 3.5,86.0 97.7(1/10.2) 50.8 4.6,560
45–54 13.3 (18/1346) 227(2/8.8) 17.0 3.9,73.1 19.3(6/311) 1.4 0.6,3.6 57.4(1/17.4) 4.3 0.6,32.1
55–64 31.7 (57/1798) 74.3(1/13.5) 2.3 0.3,16.9 91.8(33/359) 2.9 1.9,4.4 485(1/2.1) 15.3 2.1,110
65–74 63.8 (55/862) 0(0/0) 73.9(11/149) 1.2 0.6,2.2 0 (0/0)
75+ 110 (39/352) 0(0/0) 174(7/40.2) 1.6 0.7,3.5 0 (0/0)
Total: 31.7(171/5398) 89.3 (3/33.6) 4.7# 1.5,14.6 60.6(63/1040) 2.1# 1.6,2.8 101(3/29.7) 7.9# 2.5,24.9
*Indicates current age, i.e. individuals can contribute to several age groups.
† MR = mortality rate per 1000 person years of observation.
‡ MRR = Mortality rate ratio, comparing with HIV-negative.
§CI = confidence interval.
# Adjusted for age and current HIV status in a Poisson regression, see statistical methodsRetrovirology 2007, 4:85 http://www.retrovirology.com/content/4/1/85
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follow-up could contribute to higher mortality if the
course of a newly acquired HIV infection were rapid. The
few HIV seroconversions during follow-up that we know
of were adjusted for in the analyses. The mortality risk in
the present study is slightly higher than the 1.5–2 fold
increased HTLV-I mortality found in high prevalent areas
such as southern Japan [33-35]. Diseases usually associ-
ated with HTLV-I infection are Tropical spastic parapare-
sis/HTLV-I-associated myelopathy (TSP/HAM) [36,37]
and adult T-cell leukemia (ATL) [38,39] and occur in 3–4
percent of HTLV-I-infected individuals [40-42]. There are
no data regarding the prevalence and incidence of these
diseases from the area but it seems unlikely that these
would explain all the excess mortality. The high incidence
of Tuberculosis (Tb) in this community [43] might con-
tribute to this increased HTLV-I-associated mortality.
Increased prevalence of HTLV-I in Tb patients compared
with healthy individuals has been reported from Brazil
[44]. It could also reflect other causes of disease and death
that have so far not been linked to HTLV-I. In the subset
of data where concurrent HIV and HTLV-I result was avail-
able, we found no significant difference in the mortality
risk for HIV-2/HTLV-I dual infection and the mortality
risk for HIV-2 and HTLV-I single infection respectively.
Further follow-up studies of HTLV-I single and HTLV-I/
HIV dually infected individuals are needed, as are studies
identifying diseases associated with HTLV-I infection in
this area.
We have previously found that dual retroviral infections
are more common in women than in men, and that the
prevalence increases with age in women, while it
decreases with age in men [8]. In the present study we
could not identify any gender differences in HIV and
HTLV-I-associated mortality explaining our previous
observation. However, according to Table 1 more HIV-1
and dual HIV-1/HIV-2 positive-men than women moved
during follow-up compared with HIV-negative individu-
als. This was also seen for HTLV-I-positive men. The indi-
viduals who moved were censored on the date of
migration. Thus informative censoring could occur in our
analyses if the reason for having migrated was associated
with a higher or lower risk of dying. The HIV-1-positive
men who moved were younger than those who did not
move (data not shown) so this could potentially bias our
results. However, if higher HIV-associated mortality in
men would explain the higher prevalence of dual infec-
tions among women, this may rather be due to HIV-2 and
dual infection-related mortality, viewing the epidemio-
logical features of the viruses in this population. HIV-2
has been endemic in the country for decades, while HIV-
1 was introduced more recently, as illustrated by inci-
dence data which did not show any sero-conversion to
HIV-2 in individuals already infected with HIV-1 or HTLV-
I [8]. For HIV-2 there was no difference in loss to follow-
up between men and women that could bias the results
with regard to HIV-2-associated mortality. The additional
risk of dying associated with HIV was higher in younger
individuals than in older. Though only statistically signif-
icant for HIV-2 in women, the trend was seen for both
men and women regarding both HIV-1 and HIV-2, prob-
ably reflecting higher background mortality in older indi-
Table 6: Mortality rates (MRs) and mortality rate ratios (MRRs) for HTLV-I according to age and sex, irrespective of HIV status
HTLV-I-negative HTLV-I-positive
Age group* MR†(deaths/pyo) MR†(deaths/pyo) MRR‡ 95%CI§
MEN
35–44 7.0(3/426) 88.2 (1/11.3) 12.5 1.3, 120.3
45–54 29.7(11/371) 0 0/16.0)
55–64 43.6(20/458) 0 (0/26.5)
65–74 78.3(25/319) 396(5/12.6) 5.1 1.9,13.2
75+ 155(20/129) 144(1/6.9) 0.9 0.1,6.9
Total: 46.4(79/1703) 95.4(7/73.4) 1.9 # 0.9,4.0
WOMEN
35–44 5.5 (3/545) 99.9 (2/20.0) 18.2 3.0,109
45–54 13.4(5/372) 0 (0/67.0)
55–64 45.9(28/610) 88.2(9/102) 1.9 0.9,4.1
65–74 64.8(23/355) 54.2(2/36.9) 0.8 0.2,3.6
75+ 82.3 (10/122) 121(2/16.5) 1.5 0.3, 6.7
Total: 34.0(69/2004) 61.9(15/242) 1.6 # 0.9,2.8
*Indicates current age, i.e. individuals can contribute to several age groups.
† MR = mortality rate per 1000 person years of observation.
‡ MRR = Mortality rate ratio, comparing with HTLV-negative.
§CI = confidence interval.
# Adjusted for age in a Poisson regression, see statistical methodsRetrovirology 2007, 4:85 http://www.retrovirology.com/content/4/1/85
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viduals. A comparison between age groups is, however,
difficult to interpret as we have no information on when
the individuals contracted their retrovirus infections. But
also in previous follow-up studies of HIV-2 [16,17] HIV-
2-associated mortality was found to be higher among
younger individuals.
The present data indicate that there is no differential mor-
tality between men and women explaining the higher
prevalence of dual retroviral infections in older women,
nor could it be explained by behavioural factors [7,8].
This might provide further indirect support for the
hypothesis of an enhanced biological susceptibility to ret-
roviral infections of older women compared with men
[45-47]. The major change around 45 years of age corre-
sponds to the pre-menopausal and menopausal age. Alter-
ations in female hormones and the associated histological
changes could induce changes in the immunological
defence of the genital tract (reviewed in [48]). In animal
models of HIV infection it has been demonstrated that
susceptibility to SIV is related to hormonal status [49-51].
Further epidemiological studies on incidence patterns as
well as biological studies are warranted to determine the
generality and mechanisms of this trend towards
increased HIV prevalence among older women. This trend
could have major public health implications with the
longer survival of HIV-infected individuals, and older
women might constitute a vulnerable group to be empha-
sized in future HIV/AIDS prevention control programmes.
Conclusion
HIV-1-associated mortality was 4–5-fold, and HIV-2-asso-
ciated mortality was 2-fold higher than HIV-negative mor-
tality. The mortality risk for HIV-1/HIV-2 dual infection
was equivalent to the risk for HIV-1. HTLV-I MRR was
2.3(1.3–3.8) when HIV-positive individuals were
excluded from the analysis. There was no difference
between men and women explaining the previous finding
of higher prevalence of dual infections in older women.
Methods
Study area and population
The study area is divided into three adjacent districts,
Bandim 1, Bandim 2, and Belem. A community-based
cohort, established in 1987 [2,17,52] and including indi-
viduals >15 years of age from 100 randomly selected
houses, was extended in 1995 to encompass an additional
212 randomly selected houses [3]. Surveys in this cohort
were performed in 1987, 1989, 1992, and 1996
[2,3,17,52]. A second cohort, established in 1990,
included all individuals aged 50 years and over resident in
Bandim 1 and 2 based on a general population census in
1986–1987 and was extended in 1994 to encompass all
individuals aged ≥ 50 years from the entire study area
[4,53]. Surveys in this cohort were performed in 1990 and
1994. Laboratory methods have been described elsewhere
[2-4,17,52,53]. Subjects from both cohorts aged 35 years
and over at the beginning of 1998 were included in a sur-
vey of HIV and HTLV infections in 1998–2000. The rea-
son for this was to assess the dynamics of retroviruses in
older age groups, as previous studies from the area had
suggested a higher susceptibility to HIV-2 in women older
than 45 years of age [17,54]. The study included 3,560
subjects [8]. All individuals who had an HIV or HTLV sta-
tus from any of the previous surveys during 1987–1996
(N = 2,944 and N = 1,124 for HIV and HTLV respectively)
were enrolled in the present mortality analyses (Tables 1
&2).
Date of entry into the present study was the date corre-
sponding to the date of first participation ever in a screen-
ing. Information on vital status was obtained during the
study performed in 1998–2000. If a participant had died
or moved, a family member or a neighbour provided this
information. Date of exit from the study ranged from
1987 to 2000.
Statistical methods
Mortality rates (MRs) were defined as the number of
deaths per 1000 person years of observation (pyo). Date
of exit for survivors was defined as the date during the fol-
low-up study in 1998–2000 at which the subject was
encountered alive. For those who had moved or died, fol-
low-up time was censored at the midpoint of the month
when only the month for migration/death was given, and
at the midpoint of the year when only the year was given.
If the date of migration or death was missing (N = 156),
follow-up time was censored at the midpoint between
date of entry into the study and the date on which the
information about migration or death was obtained,
because more specific information was not available.
Poisson regression was used in the mortality analyses giv-
ing mortality rate ratios (MRRs) and their 95 percent CIs,
controlling for current age during follow-up (35–44,
45–54, 55–64, 65–74, 75+ years) and current HIV status
[55]. This was done for HIV-1, HIV-2, and HIV-1 + HIV-2
dual infections in the same model. Date of first participa-
tion in any screening or date of turning 35 years old, was
used as date of entry in analyses, which ever came last. To
account for possible seroconversion during the follow-up
period, the dataset records for sero-converters were split
into episodes before and after seroconversion, i.e. at date
of first positive sample. To test if men and women had
equal mortality risk associated with retrovirus infections,
we tested the interaction between gender and infection in
the Poisson regression, i.e a homogeneity test. To assess
whether age had an effect on the HIV-related excess mor-
tality, we performed a test of homogeneity with age
divided into below and over 45 years of age. In this anal-
ysis the HIV-1 infection group includes both HIV-1 andRetrovirology 2007, 4:85 http://www.retrovirology.com/content/4/1/85
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HIV-1 + HIV-2 dual infections since there were too few
HIV-1 cases to permit further division into age groups.
Analyses were performed in Stata version 8.
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